1. Scrip
  2. >>Business

US-China Decoupling Gets On Biotech's Nerves

Wakeup Call For Companies, Experts Say

 
• By Brian Yang

The Biden Administration’s latest Executive Order is aimed at shoring up investment in the US and securing supply chains for pharma and biotech products and is already impacting China's CDMO sector, but the long-term impact may be more nuanced, experts predict.

Biden issues EO to shore up biotech production and supply chain
BIDEN DECOUPLING US BIOTECH PRODUCTION SUPPLY CHAINS FROM CHINA, ANALYSTS SAY • Source: Shutterstock

Business confidence within the Chinese biotech contract manufacturing sector is being shattered by the Biden Administration’s latest move to encourage investment in US domestic biotech manufacturing capabilities.

An Executive Order (EO) issued by the US president on 12 September aims to secure US biologics manufacturing and supply chains and the message is clear - Washington is shoring up support for key industry sectors such as semiconductors and now biotech, and will work with its own industries to better compete with China

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Supply Chain

More from Business

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.